肿瘤行为由其与肿瘤微环境（TME）的相互作用所决定。嵌合抗原受体（CART）细胞疗法代表了一种新的细胞免疫疗法。免疫细胞对放疗（RT）具有不同的敏感性。RT既可以通过改变TME并诱发DNA损伤来影响肿瘤细胞，但具体效果取决于低剂量和高剂量的应用，并可能促进CART细胞的表达。CART细胞是患者基因工程修饰的T细胞，能识别肿瘤细胞表面结构并消灭其。高剂量放疗（HDRT，> 10-20 Gy/分割）通过诱导坏死、大量炎症和死亡，将免疫“冷”肿瘤转化为“热”肿瘤。低剂量放疗（LDRT，> 5-10 Gy/分割）增加了CART细胞的扩增并导致非免疫性死亡。创新的方法，即LATTICE技术，结合了在FDG高摄取区进行的高剂量和对肿瘤周边进行的低剂量。RT与免疫检查点抑制剂的联合应用增加了肿瘤的免疫原性和免疫应答，无论在接受放疗和未接受放疗的部位。本综述的目的是阐明迄今为止关于CART细胞疗法及其可能与固体肿瘤放疗的关联的知识。

Tumor behavior is determined by its interaction with the tumor microenvironment (TME). Chimeric antigen receptor (CART) cell therapy represents a new form of cellular immunotherapy (IT). Immune cells present a different sensitivity to radiation therapy (RT). RT can affect tumor cells both modifying the TME and inducing DNA damage, with different effects depending on the low and high doses delivered, and can favor the expression of CART cells. CART cells are patients' T cells genetically engineered to recognize surface structure and to eradicate cancer cells. High-dose radiation therapy (HDRT, >10-20 Gy/fractions) converts immunologically "cold" tumors into "hot" ones by inducing necrosis and massive inflammation and death. LDRT (low-dose radiation therapy, >5-10 Gy/fractions) increases the expansion of CART cells and leads to non-immunogenetic death. An innovative approach, defined as the LATTICE technique, combines a high dose in higher FDG- uptake areas and a low dose to the tumor periphery. The association of RT and immune checkpoint inhibitors increases tumor immunogenicity and immune response both in irradiated and non-irradiated sites. The aim of this narrative review is to clarify the knowledge, to date, on CART cell therapy and its possible association with radiation therapy in solid tumors.